AbbVie Inc. (ABBV)

$80.36 (As of 04/21/20)

Price Target (6-12 Months): **$89.00**

Long Term: 6-12 Months	**Zacks Recommendation:** (Since: 05/07/19) Prior Recommendation: Underperform	**Neutral**
Short Term: 1-3 Months	**Zacks Rank:** (1-5)	**3-Hold**
	Zacks Style Scores:	VGM:A
	Value: B | Growth: B | Momentum: C	

Summary

AbbVie's Humira sales are beig driven by strong demand trends amid new competition. It has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. It also has an impressive late-stage pipeline. Its two new drugs, Skyrizi and Rinvoq, were off to a strong start and have significant potential. The acquisition of Allergan, if successful, should diversify AbbVie's revenue base and accelerate its non-Humira business. However, its shares have underperformed the industry this year. Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind. Also, the decline in HCV sales and uncertainty about the coronavirus impact is a concern. Estimates have declined ahead of Q1 earnings. AbbVie has a positive record of earnings surprise in the recent quarters.

Price, Consensus & Surprise

Data Overview

52 Week High-Low	**$97.86 - $62.55**
20 Day Average Volume (sh)	**11,497,420**
Market Cap	**$124.0 B**
YTD Price Change	**-5.1%**
Beta	**0.84**
Dividend / Div Yld	**$4.72 / 5.6%**
Industry	**Large Cap Pharmaceuticals**
Zacks Industry Rank	**Top 11% (29 out of 253)**
Last EPS Surprise	**0.5%**
Last Sales Surprise	**0.0%**
EPS F1 Est- 4 week change	**-3.5%**
Expected Report Date	**05/01/2020**
Earnings ESP	**-0.3%**
P/E TTM	**9.4**
P/E F1	**7.9**
PEG F1	**1.4**
P/S TTM	**3.7**

Sales and EPS Growth Rates (Y/Y %)



Sales Estimates (millions of $)

	Q1	Q2	Q3	Q4	Annual*
2021	12,955 E	13,314 E	13,591 E	14,066 E	53,927 E
2020	8,289 E	12,179 E	13,090 E	13,736 E	47,180 E
2019	7,828 A	8,255 A	8,479 A	8,704 A	33,266 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	$2.83 E	$2.94 E	$3.03 E	$3.16 E	$11.83 E
2020	$2.27 E	$2.36 E	$2.67 E	$2.88 E	$10.16 E
2019	$2.14 A	$2.26 A	$2.33 A	$2.21 A	$8.94 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 04/21/2020. The reports text is as of 04/22/2020.

Overview





North Chicago, IL-based AbbVie is expected to become one of the top-most pharma companies after it closes its pending acquisition of Botox maker Allergan in a cash-and-stock deal for $63 billion this year. The deal is expected to transform AbbVie's portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. It announced the definitive agreement to buy Allergan on Jun 24, 2019. AbbVie will pay Allergan a price of $120.30 in cash and 0.8660 AbbVie shares per Allergan share. The deal, if it gets all necessary approvals, is expected to close in the first half of 2020.

AbbVie has a presence in the rheumatoid arthritis, cancer, psoriasis, Crohn's disease, HIV, hepatitis C virus (HCV), thyroid disease, Parkinson's disease, ulcerative colitis, endometriosis and cystic fibrosis markets.

Humira is approved for several autoimmune diseases like rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica (hematological cancers – approved for five different disease areas) became part of the company's portfolio following the Pharmacyclics acquisition. Humira and Imbruvica accounted for 58% and 14%, respectively, of AbbVie's total revenues in 2019.

Other drugs include Mavyret/Maviret (HCV), Venclexta (venetoclax) (oncology), AndroGel (low testosterone), Kaletra (HIV), Synthroid (hormone therapy for thyroid disease), Creon (pancreatic enzyme replacement therapy for conditions associated with cystic fibrosis and chronic pancreatitis), Duopa/Duodopa (advanced Parkinson's disease), Orilissa (endometriosis pain), Skyrizi (plaque psoriasis) and Rinvoq (RA). The company also has partnerships with companies like Roche and J&J.

In June 2016, AbbVie acquired cancer drugmaker, Stemcentrx in a cash and stock deal worth $5.8 billion.

AbbVie reported total sales of $33.3 billion in 2019, up 1.6%.

Reasons To Buy:

AbbVie's key drug Humira has been performing well. Imbruvica has multi-billion dollar potential. AbbVie has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta.

- **Humira U.S. Sales Going Strong:** AbbVie's flagship product, Humira, continues to drive revenues. Humira, an anti-inflammatory product, is the anti-tumor necrosis factor (TNF) drug of choice. Humira continues to witness strong demand trends despite new mechanisms of action and competition from indirect biosimilars. Currently approved for 12 indications, Humira sales have increased consistently backed by robust demand trends. The product continues to see strong growth in the dermatology and gastroenterology markets in the United States.

  Though biosimilar versions of Humira are already approved by the FDA, per settlements with several companies, biosimilar entry into the United States is scheduled for 2023, thus delaying direct biosimilar competition in the country.

- **Allergan Deal, If Successful, Will Add Botox:** AbbVie's rationale behind the Allergan deal is to add a new blockbuster product to its portfolio, Allergan's Botox, ahead of generic competition for Humira. Humira generics are already denting revenues in Europe and are expected to be launched in the United States in 2023. AbbVie is heavily dependent on Humira and is looking to diversify its portfolio. Approved for therapeutic and aesthetic use, Botox is a key top-line driver for Allergan and looks fit to be the next revenue driver for AbbVie after Humira loses exclusivity. Overall, the Allergan acquisition should diversify AbbVie's revenue base to markets/categories outside AbbVie's present drug portfolio and accelerate its non-Humira business.

- **Collaborations and Agreements to Strengthen Pipeline:** We are positive on AbbVie's efforts to strengthen its pipeline. The company has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas including oncology, immunology, neuroscience, cystic fibrosis and women's health. Some partners include Roche (Venclexta – oncology), J&J (Imbruvica – cancer) and Boehringer Ingelheim (Skyrizi– psoriasis) among others. We believe the company will continue pursuing such deals to grow its pipeline.

- **Growing Oncology Portfolio:** AbbVie believes that oncology will be its major growth driver over the next 10 years. The acquisition of Pharmacyclics in May 2015 added Imbruvica to AbbVie's portfolio and diversified the company's revenue base. AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta, which generated combined revenues of nearly $5.5 billion in 2019. Strong double-digit growth is expected in 2020.

  Imbruvica, currently approved for quite a few indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases. Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments. AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020. AbbVie is positioning Imbruvica as a "pipeline in a molecule" - the treatment is in several company-sponsored studies.

  AbbVie is also studying Venclyxto/Venclexta to expand the label to address the broader relapsed/refractory CLL patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies like multiple myeloma and AML. AbbVie expects to begin a phase III study on Venclexta in myelodysplastic syndrome or MDS in 2020. Label expansion approvals in the past couple of years have expanded the eligible patient population of Venclexta significantly, which is boosting sales from the drug.

- **Promising Pipeline:** AbbVie has a deep pipeline consisting of several interesting late-stage candidates. Key recent FDA approvals include that of Orilissa (elagolix) for management of pain associated with endometriosis, a common gynecologic disorder in July 2018, Skyrizi (risankizumab) for plaque psoriasis in April 2019 and Rinvoq (upadacitinib) for moderate-to-severe rheumatoid arthritis (RA) in August 2019. Skyrizi and Rinvoq have demonstrated differentiated clinical profiles versus Humira and are expected to lower AbbVie's dependence on Humira. Importantly, Skyrizi and Rinvoq are off to strong starts and AbbVie expects combined revenues of these two drugs to be approximately $1.7 billion in 2020.

  Promising candidates include elagolix (under review for heavy menstrual bleeding associated with uterine fibroids), risankizumab (phase III for Crohn's disease and psoriatic arthritis, phase II for ulcerative colitis) upadacitinib (phase III for Crohn's disease, ulcerative colitis, axial spondyloarthritis, atopic dermatitis and giant cell arteritis; psoriatic arthritis – NDA filing expected in second quarter of 2020), navitoclax (phase III for myelofibrosis to begin in first half of 2020) ABBV-8E12 (phase II for early Alzheimer's disease), veliparib (NDA for ovarian cancer and BRCA-mutated breast cancer to be filed in first half of 2020), ABBV-951 (phase III for Parkinson's disease) and ABBV-599/JAK inhibitor/BTK inhibitor combination (phase II for rheumatoid arthritis).

  AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023.

Reasons To Sell:

Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind.

- **Shares Underperforming Industry**: AbbVie shares have declined 4.5% this year compared with the industry's 1.3% decrease.

- **Humira Biosimilars Can Erode Sales:** Several companies have made biosimilar versions of Humira. With Humira accounting for around 60% of AbbVie's sales, the entry of biosimilars would have a huge impact on the company's financials. Per settlements with nine manufacturers, Humira biosimilars are expected to be launched in the United States in 2023. In the international markets, AbbVie is facing direct biosimilar competition in Europe and other countries. Humira biosimilars were launched in the EU in October 2018 and are rapidly eroding international sales from the branded drug. Humira international sales declined 31.1% in 2019 due to generic competition. Humira sales could also feel the impact of competition from biosimilar versions of other products like Remicade and Enbrel.

- **Declining HCV Sales:** AbbVie's global HCV sales declined almost 18% on an operational basis in 2019. The performance of Viekira, AbbVie's all-oral, interferon-free therapy with/without ribavirin (RBV), has been below market expectation since 2016 as it experienced market share loss and price erosion due to competitive dynamics within the HCV market.

  Sales of AbbVie's relatively newer HCV medicine, Mavyret declined in 2018 and 2019 primarily driven by lower patient volumes in certain international markets and competitive dynamics in the United States.

- **Intense Competition for Key Products:** While Humira U.S. sales continue to be impressive, we are concerned about intense competition in the market in the form of Johnson & Johnson's Simponi and UCB's Cimzia among others. Increasing competition from new classes of drugs could lead to a slowdown in Humira's market share gains. Meanwhile, Kaletra faces intense competition in the HIV market from players like Gilead, Bristol-Myers, and Johnson & Johnson.

- **Pipeline and Regulatory Setbacks:** While we believe that AbbVie has an impressive pipeline, we note that clinical development involves a high degree of risk. Gaining approval for pipeline candidates has become more difficult given the tough regulatory environment. Development and regulatory setbacks for late-stage pipeline candidates would be a major disappointment for the company.

  In April 2017, AbbVie announced that two phase III studies evaluating its PARP inhibitor, veliparib in combination with chemotherapy for squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) failed to meet their primary endpoints. Based on the data, AbbVie discontinued development in these indications.

  In August 2019, AbbVie discontinued development of rovalpituzumab tesirine or Rova-T due to poor/no survival benefit observed for patients treated with Rova-T in three studies. Rova-T was added to AbbVie's portfolio, following the acquisition of Stemcentrx in June 2016. The failure of Rova-T has brought into question the viability of the Stemcentrx deal.

  In March 2019, the FDA placed a partial clinical hold on all studies evaluating Venclexta for the treatment of multiple myeloma. The decision was taken after, in the ongoing phase III BELLINI study, a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the study. In May 2019, a phase III study evaluating depatuxizumab mafodotin (Depatux-M) failed to show any survival benefit in patients with newly diagnosed glioblastoma, an aggressive form of brain cancer. As a result, AbbVie stopped enrollment in all ongoing Depatux-M studies.

Last Earnings Report

AbbVie Beats on Q4 Earnings & Sales

Quarter Ending	12/2019
Report Date	**Feb 07, 2020**
Sales Surprise	**0.03%**
EPS Surprise	**0.45%**
Quarterly EPS	**2.21**
Annual EPS (TTM)	**8.94**

Fourth-quarter 2019 earnings of $2.21 per share beat the Zacks Consensus Estimate of $2.20 and came in higher than the company's guided range of $2.17-$2.19. Earnings rose 16.3% year over year.

Revenues of $8.70 billion came in line with the Zacks Consensus Estimate. Sales rose 4.8% on a reported basis. Excluding currency headwinds of 0.5%, operational revenues increased 5.3%, driven by continued strong performance of AbbVie's immunology and hematological oncology despite the impact of international biosimilar competition for Humira. Operational revenue growth was slightly ahead of the guidance of approximately 5%.

Quarter in Details

Humira sales were flat (up 0.5% on an operational basis) at $4.92 billion as higher U.S. sales were offset by decline in international markets.

Sales in the United States climbed 9.8% to $3.97 billion. However, Humira sales in the ex-U.S. markets were down 25.4% on an operational basis and 27.3% on a reported basis to $948 million.

International sales were severely impacted by the launch of several direct biosimilar drugs in Europe and other international markets.

In 2020, Humira is expected to record revenue growth of approximately 9% in United States. International Humira sales are expected to approach $3.4 billion in 2020.

New immunology drugs Skyrizi and Rinvoq registered sales of $216 million and $33 million, respectively. In the previous quarter, Skyrizi and Rinvoq recorded sales of $91 million and $14 million, respectively. Per the company, both Skyrizi and Rinvoq are off to an impressive start.

Regarding Rinvoq, on the call, the company said that the early uptake trends were robust and the medicine currently covers approximately 9% of in-play RA patients.

AbbVie expects Skyrizi and Rinvoq combined revenues of approximately $1.7 billion in 2020, higher than $1 billion expected previously. This includes Skyrizi global revenues of approximately $1.2 billion and Rinvoq global revenues of approximately $500 million.

AbbVie's oncology/hematology (including Imbruvica and Venclexta) sales surged 37.2% on an operational basis to $1.55 billion in the quarter, driven by strong growth of both Imbruvica and Venclexta.

Fourth-quarter net revenues from Imbruvica were $1.3 billion, up 28.9% year over year. U.S. sales of Imbruvica grossed $1.07 billion, up 28% from the year-ago figure, driven by strong share in all lines of therapy in CLL. AbbVie logged $223 million of international profit sharing with J&J, up 33.8% year over year.

Venclexta brought in revenues of $251 million, up more than 100% year over year driven by continued share gains across all approved indications.

In 2020, Imbruvica global revenues are expected to be approximately $5.5 billion while Venclexta global sales are expected to be approximately $1.3 billion

HCV products, including Viekira and Mavyret, recorded sales of $632 million, down 26.7% (down 26.4% on an operational basis) year over year on lower sales of Mavyret as well as Viekira. In the United States, HCV revenues declined 25.1% to $306 million. International HCV revenues declined 27.6% on an operational basis to $326 million.

Mavyret sales totaled $628 million in the quarter, down 23.4% (down 23.1% on an operational basis) year over year due to a decline in the United States as well as international markets. International sales of Mavyret declined 20.8% in the third quarter on an operational basis due to lower treated patient volumes in some markets. U.S sales were down 5.4% year over year due to increased competition in management Medicaid segment.

Other products that delivered an encouraging performance include Duodopa. It recorded revenue growth of 7.1% on an operational basis to $118 million. Creon witnessed an increase of 11.5% in revenues to $292 million. Drugs that recorded sales decline include Synthroid, Lupron, Synagis, Androgel, Kaletra and Sevoflurane. Creon and Synthroid generate sales only from U.S. markets.

Newly launched drug Orilissa recorded sales of $34 million, entirely from the U.S. market versus $27 million in the previous quarter. The sales ramp up of the drug has been slower than expected.

Margins Rise

Adjusted gross margin rose 180 bps to 81.6% in the quarter. Adjusted gross margin included benefit due to low Humira royalties owed. Adjusted SG&A expenses increased 4.8% to $1.9 billion. R&D expenses were $1.33 billion in the fourth quarter, sliding 2.8% year over year due to greater investments in the pipeline. Adjusted operating margin represented 44.6% of sales in the reported quarter, up 290 bps year over year.

2019 Results

Full-year 2019 sales rose 1.6% to $33.27 billion. Sales were up 2.7% on an operational basis, slightly above the guidance range of approximately 2.5% growth.

Adjusted earnings for 2019 of $8.94 per share were above the guided range of $8.90-$8.92. Earnings rose 13% year over year.

2020 Outlook

AbbVie expects adjusted EPS to be in the range of $9.61-$9.71 for 2020 for the standalone company, which means excluding Allergan. The earnings guidance indicates a year-over-year increase of 8.1% at the mid-point.

The company also expects standalone revenue growth to approach 8% on an operational basis. Currency headwinds are expected to have a minimal impact on reported sales growth in 2020.

Adjusted gross margin is expected to be approximately 81.5% of sales in 2020. Operating margin is expected to be approximately 48% of sales. While R&D is expected to be slightly above 14% of sales, SG&A is expected to be above 19% of sales

First-Quarter 2020 Outlook

First-quarter earnings are expected between $2.28 and $2.30 per share. Operational sales growth is expected to be approximately 7%.

U.S. Humira sales are expected to be approximately $3.5 billion while international Humira sales are expected to be approximately $900 million. Imbruvica sales are expected to approach $1.2 billion. For Skyrizi, global sales are expected to be approximately $250 million.

Recent News

COVID-19 Relief Efforts – Mar 31

AbbVie announced that it is donating $35 million for COVID-19 relief to support healthcare systems, patients and communities. AbbVie also announced a partnership with International Medical Corps, Direct Relief and Feeding America to increase healthcare capacity, supply critical equipment and deliver food and essential supplies.

Venclexta Combo Meets Endpoints in Leukemia Study – Mar 23

Abbvie announced positive interim analysis data from a phase III study — VIALE-A — evaluating a combination regimen of Venclexta plus azacitidine (Vidaza) in previously-untreated acute myeloid leukemia ("AML") patients who are ineligible for intensive chemotherapy.

Data from the first interim analysis of the VIALE-A study showed that the Venclexta combo met the study's co-primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi), compared to placebo plus azacitidine.

An independent data monitoring committee recommended early report of the study data and submission to regulatory authorities based on positive efficacy results. Detailed data from the study will be presented at a future medical meeting or published in a peer-reviewed journal.

Signs Consent Decree with FTC Staff – Mar 17

AbbVie and Allergan announced that they have entered into a consent decree agreement with the staff of the U.S. Federal Trade Commission (FTC) per which they have agreed to divest brazikumab to AstraZeneca and Zenpep to Nestle. The consent decree remains subject to further review and approval by the Commissioners of the FTC

Venclexta+Gazyva Get EU Approval in First-Line CLL – Mar 12

AbbVie and Roche announced that the European Commission approved a combination of Venclyxto (called Venclexta in United States) and Roche's Gazyva as a fixed-duration treatment for first-line chronic lymphocytic leukemia (CLL). The approval was based on data from the phase III CLL14 study. The approval was expected as the CHMP had given a positive opinion recommending approval of the combination in January. The combination was approved for the same indication by the FDA in May last year.

Backs Studies on HIV Drug Kaletra for Coronavirus Cure – Mar 9

AbbVie announced that it is working with global health authorities to determine the efficacy of its HIV medicine, Kaletra/Aluvia against COVID-19. AbbVie is coordinating with European health authorities, FDA, Centers for Disease Control and Prevention and other U.S. health agencies to support clinical studies on Kaletra/Aluvia for COVID-19 treatment. Kaletra/Aluvia is a combination of lopinavir and ritonavir.

AbbVie donated Aluvia to the government of China after a request was made in January for experimental use in COVID-19 treatment. AbbVie claims that Aluvia has reportedly been effective in treating COVID-19. However, the company ensured no disruption in the supply of Kaletra/Aluvia for HIV treatment due to the experimental use of this therapy against COVID-19.

EC Approves Shorter Duration Mavyret – Mar 6

AbbVie announced that the European Commission has approved a change to the marketing label of Mavyret. The approval is to shorten the once-daily treatment duration of Mavyret from 12 to 8 weeks for treatment-naïve HCV patients with compensated cirrhosis with genotype (GT) 3 infection. MAVIRET is currently approved as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis. Maviret is now the only pan-genotypic (GT1-6) 8-week treatment option for HCV patients, without cirrhosis or with compensated cirrhosis, regardless of genotype. The label expansion was supported by data from the phase EXPEDITION-8 study.

Valuation

AbbVie's shares are down 4.5% in the year-to-date period but up 7.4% over the trailing 12-month period. Stocks in the Zacks sub-industry and sector are down 1.3% and 4%, respectively in the year-to-date period. Over the past year, stocks in the sub-industry and sector are up 14% and 4.1%, respectively.

The S&P 500 Index is down 10.9% in the year-to-date period and 1.7% in the past year.

The stock is currently trading at 7.69X forward 12-month earnings per share, which compares to 14.86X for the Zacks sub-industry, 21.34X for the Zacks sector and 19.52X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 16.6X and as low as 6.93X, with a 5-year median of 11.37X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our $89 price target reflects 8.1 X forward 12-month earnings per share.

The table below shows summary valuation data for ABBV

Valuation Multiples - ABBV

		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	7.69	14.86	21.34	19.52
	5-Year High	16.6	18.12	21.34	19.52
	5-Year Low	6.93	13.04	15.81	15.19
	5-Year Median	11.37	15.38	18.81	17.45
P/S F12M	Current	2.5	4.63	2.71	3.2
	5-Year High	6.22	4.83	3.84	3.44
	5-Year Low	2.5	3.92	2.25	2.54
	5-Year Median	3.74	4.39	2.96	3.01
P/FCF	Current	9.77	20.59	16.72	20.77
	5-Year High	29.13	25.3	21.69	36.11
	5-Year Low	7.49	16.49	13.31	16.51
	5-Year Median	14.15	19.81	17.55	23.01

As of 4/20/2020

Industry Analysis **Zacks Industry Rank:** Top 11% (29 out of 253)

Top Peers

Company (Ticker)	Rec	Rank
Eli Lilly and Company **(LLY)**	Outperform	2
Amgen Inc. **(AMGN)**	Neutral	3
AstraZeneca PLC **(AZN)**	Neutral	3
Johnson & Johnson **(JNJ)**	Neutral	3
Merck & Co., Inc. **(MRK)**	Neutral	2
Novartis AG **(NVS)**	Neutral	3
Pfizer Inc. **(PFE)**	Neutral	2
Roche Holding AG **(RHHBY)**	Neutral	3

Industry Comparison Industry: Large Cap Pharmaceuticals

Industry Peers

	ABBV	X Industry	S&P 500	AMGN	JNJ	MRK
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	2
VGM Score	A	-	-	D	C	B
Market Cap	124.03 B	139.24 B	19.37 B	139.06 B	399.86 B	210.76 B
# of Analysts	3	3	14	13	9	7
Dividend Yield	5.62%	2.51%	2.23%	2.70%	2.51%	2.94%
Value Score	B	-	-	B	C	B
Cash/Price	0.32	0.06	0.05	0.06	0.05	0.05
EV/EBITDA	12.31	13.46	11.66	12.44	16.51	14.76
PEG Ratio	1.42	1.95	2.20	1.62	3.24	2.16
Price/Book (P/B)	NA	4.17	2.61	14.53	6.71	8.14
Price/Cash Flow (P/CF)	8.13	11.50	10.30	12.51	13.17	12.42
P/E (F1)	7.91	14.69	17.85	15.43	19.72	14.69
Price/Sales (P/S)	3.73	4.42	2.04	5.95	4.83	4.50
Earnings Yield	12.10%	6.81%	5.48%	6.48%	5.07%	6.81%
Debt/Equity	-7.71	0.57	0.71	2.79	0.45	0.87
Cash Flow ($/share)	10.33	4.33	7.01	18.91	11.52	6.69
Growth Score	B	-	-	D	B	B
Hist. EPS Growth (3-5 yrs)	21.82%	8.34%	10.92%	10.57%	9.40%	8.10%
Proj. EPS Growth (F1/F0)	13.65%	8.06%	-3.67%	3.45%	-11.38%	8.97%
Curr. Cash Flow Growth	8.78%	4.27%	5.93%	-2.47%	3.68%	5.54%
Hist. Cash Flow Growth (3-5 yrs)	19.92%	7.62%	8.55%	5.06%	7.62%	0.15%
Current Ratio	3.18	1.26	1.24	1.44	1.26	1.24
Debt/Capital	NA%	39.95%	42.83%	73.59%	30.82%	46.65%
Net Margin	23.69%	22.35%	11.64%	33.57%	24.47%	21.01%
Return on Equity	-162.54%	32.05%	16.74%	85.52%	40.01%	49.41%
Sales/Assets	0.51	0.49	0.54	0.39	0.53	0.56
Proj. Sales Growth (F1/F0)	41.83%	4.61%	-0.39%	8.04%	-2.59%	4.13%
Momentum Score	C	-	-	F	F	D
Daily Price Chg	0.65%	0.55%	-2.18%	0.69%	-0.23%	-0.43%
1 Week Price Chg	4.64%	5.04%	0.42%	7.68%	7.64%	1.18%
4 Week Price Chg	30.22%	27.18%	26.24%	27.25%	36.47%	25.15%
12 Week Price Chg	-0.04%	-3.17%	-20.02%	6.12%	1.96%	-3.48%
52 Week Price Chg	7.47%	13.12%	-12.49%	34.16%	10.04%	13.12%
20 Day Average Volume	11,497,420	4,268,865	3,036,163	3,152,070	12,414,636	11,995,503
(F1) EPS Est 1 week change	-0.55%	-0.25%	-0.14%	-0.87%	-4.64%	-0.25%
(F1) EPS Est 4 week change	-3.47%	-1.15%	-6.66%	-1.38%	-14.82%	-1.15%
(F1) EPS Est 12 week change	8.03%	-0.57%	-10.02%	-3.91%	-15.31%	2.12%
(Q1) EPS Est Mthly Chg	-5.60%	-5.35%	-9.67%	-4.13%	-35.93%	-7.26%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	B
Momentum Score	C
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock.The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment.This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time.ZIR is not a broker-dealer.ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients.Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.